ANAB
What one share of Anaptysbio holds
Pharmaceutical Preparations
AnaptysBio manages the financial collaborations for a PD-1 antagonist (Jemperli (dostarlimab-gxly) or “Jemperli”) with TESARO, Inc. (“Tesaro”), an oncology-focused biopharmaceutical subsidiary of GSK (Tesaro and GSK are hereinafter referred to, collectively, as “GSK”) and an IL-36R antagonist (“Quimilza” formerly referred to as imsidolimab) with Vanda Pharmaceuticals Inc.
Anaptysbio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.07 |
|---|---|
| Profit | $5.82 |
| Cash and investments | $4.50 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $6.33 | −$1.62 | $0.02 | −$3.44 | — | −$14.43 |
| 2017 | $0.51 | −$1.52 | $0.01 | −$1.00 | — | $12.93 |
| 2018 | $0.20 | −$2.50 | $0.04 | −$2.01 | — | $18.07 |
| 2019 | $0.30 | −$3.60 | $0.03 | −$2.60 | — | $14.86 |
| 2020 | $2.75 | −$0.73 | $0.02 | −$0.54 | — | $14.50 |
| 2021 | $2.30 | −$2.11 | $0.05 | −$1.72 | — | $12.89 |
| 2022 | $0.37 | −$4.57 | $0.01 | −$2.63 | — | $9.19 |
| 2023 | $0.64 | −$6.08 | $0.03 | −$4.52 | — | $3.31 |
| 2024 | $3.09 | −$4.92 | $0.01 | −$4.59 | — | $2.33 |
| 2025 | $7.76 | −$0.44 | $0.00 | $0.65 | — | $1.33 |